Welcome to our dedicated page for Kinnate Biopharma news (Ticker: KNTE), a resource for investors and traders seeking the latest updates and insights on Kinnate Biopharma stock.
Kinnate Biopharma Inc. (Nasdaq: KNTE) is a clinical-stage biopharmaceutical company pioneering targeted therapies for genomically defined cancers. This dedicated news hub provides investors and researchers with essential updates on the company's kinase inhibitor pipeline, strategic partnerships, and regulatory milestones.
Access timely announcements about exarafenib development, KIN-3248 progress, and other programs from the Kinnate Discovery Engine platform. Our curated collection features press releases on clinical trial phases, FDA communications, financial updates, and global partnership agreements like the recent collaboration with Pierre Fabre Laboratories.
Key resources include updates on treatment candidates addressing BRAF, NRAS, and FGFR alterations, strategic reprioritization decisions, and operational developments. Bookmark this page for direct access to primary source materials that inform investment analysis and oncology research.
Kinnate Biopharma, focused on small molecule kinase inhibitors, presented findings at the ESMO TAT 2022 conference on BRAF Class II and III alterations in cancer patients. The study, utilizing a database of over 55,000 patients, revealed that approximately 2% have these alterations without access to approved therapies. Key findings included higher tumor mutation burden and shorter treatment durations for patients with Class II or III alterations compared to Class I. This highlights the urgent unmet medical need for targeted therapies in this population.
Kinnate Biopharma (Nasdaq: KNTE) announced that CEO Nima Farzan will present a company overview at the 42nd Annual Cowen Health Care Conference on March 9, 2022, at 1:30 PM ET/10:30 AM PT. This virtual event aims to discuss Kinnate's focus on developing small molecule kinase inhibitors for challenging cancers. Investor meetings will also be held during the conference. A live webcast will be available on the Kinnate website, along with a replay for 30 days post-event.
Kinnate Biopharma (Nasdaq: KNTE) has been selected to present preclinical data on KIN-2787, a next-generation pan-RAF inhibitor, at the IASLC 2022 Targeted Therapies of Lung Cancer meeting from February 22-26, 2022. The study focuses on KIN-2787's antitumor activity against BRAF-altered non-small cell lung cancer (NSCLC), demonstrating effectiveness in both Class II and III alterations, which represent up to 65% of BRAF alterations in NSCLC. Initial clinical trial data are expected in Q3 2022, with ongoing patient enrollment in the KN-8701 trial.
Kinnate Biopharma (Nasdaq: KNTE) has announced that CEO Nima Farzan will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022, at 3:40 PM ET. The conference will be held virtually, and Kinnate's management will also conduct investor meetings during this period. A live webcast of the presentation will be available on Kinnate's website and can be accessed for 30 days post-event. Kinnate specializes in developing small molecule kinase inhibitors for difficult-to-treat cancers.
Kinnate Biopharma has announced updates on KIN-3248, a next-generation pan-FGFR inhibitor, during the ASCO Gastrointestinal Cancers Symposium from January 20-22, 2022. KIN-3248 targets various FGFR mutations linked to drug resistance in cancers like cholangiocarcinoma. The FDA approved the Investigational New Drug application for KIN-3248 on January 18, 2022, with a Phase 1 trial set to begin in H1 2022. Preclinical studies show robust efficacy against FGFR mutations, demonstrating its potential as a targeted therapy for FGFR-altered tumors.
Kinnate Biopharma (Nasdaq: KNTE) announced FDA clearance for the IND application for KIN-3248, a new pan-FGFR inhibitor targeting intrahepatic cholangiocarcinoma (ICC) and urothelial carcinoma (UC). The Phase 1 clinical trial is set to begin in 1H 2022, assessing safety, tolerability, and efficacy in patients with FGFR2 and/or FGFR3 gene alterations. KIN-3248 aims to address acquired resistance to existing FGFR therapies, with preclinical data indicating broad inhibitory activity. The company focuses on developing targeted therapies for genomically defined cancers.
Kinnate Biopharma Inc. (Nasdaq: KNTE) has announced significant advancements in its clinical programs, focusing on KIN-2787 for NRAS-mutant melanoma. The company is expanding its ongoing KN-8701 trial to include NRAS-mutant melanoma patients and initiating combination trials with binimetinib in 2022. Kinnate plans to commence a Phase 1 trial for KIN-3248, pending FDA clearance. As of December 31, 2021, Kinnate reported approximately $324.9 million in cash, expected to fund operations through mid-2023. The company's efforts could potentially address an underserved cancer population, enhancing market opportunities.
Kinnate Biopharma, focused on small molecule kinase inhibitors, announced presentations at two key scientific meetings. The AACR Special Conference: Targeting RAS will feature a study on the prevalence of Class II and III BRAF mutation-positive solid tumors. The presentation is scheduled for January 8, 2022. Additionally, the ASCO GI Cancers Symposium, on January 21, 2022, will showcase results from preclinical studies evaluating KIN-3248, a promising FGFR inhibitor. The company aims to improve targeted therapies for genomically defined cancers.
Kinnate Biopharma Inc. (Nasdaq: KNTE) has been added to the NASDAQ Biotechnology Index (NBI), effective December 20, 2021. This selection reflects the company's progress in developing small molecule kinase inhibitors for challenging cancers. The NBI is a modified market capitalization weighted index tracking biotechnology and pharmaceutical companies, reconstituted annually based on eligibility criteria. CEO Nima Farzan noted the inclusion will enhance awareness of Kinnate's mission and pipeline, emphasizing the significant strides made in 2021.
Kinnate Biopharma (KNTE) announced its Q3 2021 financial results, reporting a net loss of $24.7 million, an increase from $10.5 million in Q3 2020. Research and development expenses surged to $18.7 million, while general and administrative costs rose to $6.1 million. The company ended the quarter with $347.9 million in cash and investments, excluding its China joint venture. Kinnate is actively enrolling patients in its KN-8701 trial for KIN-2787 and has partnered with Guardant Health to study BRAF alterations in advanced cancers, revealing 55% of BRAF-positive patients have Class II and III alterations.
FAQ
What is the market cap of Kinnate Biopharma (KNTE)?
